In a matter involving alleged abuse of the U.S. Pharmacopeia standard setting process, CRA examined market power for product dispensed through hospital and non-hospital sites of care. CRA’s expert found that in most uses, during the relevant time period there was ample evidence of competition, finding that the manufacturer at issue was effectively price constrained by existing competition.
IP Literature Watch: September 2022
Among the pieces featured in this month’s IP Literature Watch are a paper discussing the licensing of 5G SEPs by automotive manufacturers; an essay exposing...